An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Inclusion Criteria: * Documented diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening, including ileal, colonic, or ileo-colonic disease distribution * Must have had an inadequate response, loss of response, or intolerance to 1 or more of the standard treatments * Must have active moderate to severe CD * Men and women must agree to follow specific methods of contraception, if applicable Exclusion Criteria: * Severe or fulminant colitis that is likely to require surgery or hospitalization * Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including ulcerative colitis, malignant, toxic, indeterminate, etc.) other than Crohn's Disease * Previous exposure to BMS-986165 in any study * Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, psychiatric, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant Other protocol-defined inclusion/exclusion criteria apply